What is the translation of " OTHER FORMS OF INTERACTION " in Slovenian?

• druge oblike interakcij
• drugih vrstah interakcij

Examples of using Other forms of interaction in English and their translations into Slovenian

Other forms of interaction.
Druge oblike interakcij.

Interaction with other medicinal products and other forms of interaction.
Medsebojno delovanje zdravil in druge oblike interakcij.

Other forms of interaction.
Druge oblike medsebojnega delovanja.

Effects of other medicinal products on Lojuxta and other forms of interaction.
Učinki drugih zdravil na zdravilo Lojuxta in druge oblike interakcij.

Interaction with other medicinal products and other forms of interaction: Inform your veterinary surgeon if your dog is using other medicines.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Obvestite svojega veterinarja, če vaš pes dobiva druga zdravila.

Uth 4.5 Interaction with other medicinal products and other forms of interaction.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcijon.

(iii) forms of interaction with other medicinal products and other forms of interaction(e.g. alcohol, tobacco, foodstuffs) which may affect the action of the medicinal product;
(iii) oblikami medsebojnega vplivanja z drugimi zdravili ter drugimi oblikami medsebojnih vplivanja(npr. alkohol, tobak, hrana), ki lahko vplivajo na delovanje zdravila;

(viii) interaction with other medicinal products and other forms of interaction.
(viii) interakcija z drugimi zdravili ter druge oblike interakcije;

Interaction with other medicinal products and other forms of interaction: Cross resistance may occur with other macrolides.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Lahko se pojavi navzkrižna rezistenca z drugimi makrolidi.

Table 2: Interactions between Lojuxta and other medicinal products and other forms of interaction.
Preglednica 2: Medsebojno delovanje zdravila Lojuxta z drugimi zdravili in druge oblike interakcij.

No interaction studies have been performed and no other forms of interaction have been identified.
Študij medsebojnega delovanja niso izvedli niti niso ugotovili drugih oblik interakcij.

The combination of lithium and perindopril is generally not recommended(see 4.5 Interaction with other medicinal products and other forms of interaction).
Kombinacija litija in perindoprila na splošno ni priporočljiva(glejte poglavje 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij).

Interaction with other medicinal products and other forms of interaction: No data available.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Podatki niso na voljo.

Dosage of paroxetine should be increased gradually until an optimal response is reached(see section 4.3 Contraindications and section 4.5 Interactions with other medicinal products and other forms of interaction).
Odmerjanje paroksetina je potrebno povečevati postopoma dokler ni dosežen optimalen odziv(glejte poglavje 4. 3 Kontraindikacije in poglavje 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij).

Interaction with other medicinal products and other forms of interaction: For subcutaneous route:.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Za subkutano dajanje:.

There is also an increased risk of systemic side effects when combining fluticasone propionate with other potent CYP3A inhibitors(see 4.5 Interaction with Other Medicinal Products and Other Forms of Interaction).
Tveganje za sistemske neželene učinke je večje tudi med kombinacijo flutikazonijevega propionata in drugih močnih zaviralcev CYP3A(glejte 4. 5, Medsebojno delovanje z drugimi zdravili in druge oblike interakcij).

(See Section 4.5 Interaction with other medicinal products and other forms of interaction and Section 4.8 Undesirable effects.).
(Glejte poglavje 4. 5 Medsebojno delovanje zdravil in druge oblike interakcij in poglavje 4. 8 Neželeni učinki).

The combination of perindopril and potassium sparing diuretics, potassium supplements or potassium- containing salt substitutes is generally not recommended(see 4.5 Interaction with other medicinal products and other forms of interaction).
Kombinacija perindoprila in diuretikov, ki zadržujejo kalij, dodatkov kalija ali nadomestkov soli, ki vsebujejo kalij, na splošno ni priporočljiva(glejte poglavje 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij).

No interaction with other medicinal products and other forms of interaction are known.
Medsebojno delovanje s katerimkoli drugim zdravilom za uporabo v veterinarski medicini in ostale oblike medsebojnega delovanja niso znane.

Physicians should advise patients on appropriate sun protection measures, such as minimisation of the time in the sun, use of sunscreen product and covering the skin with appropriate clothing(see Section 4.5“Interaction with other medicinal products and other forms of interaction”).
Zdravniki morajo bolnikom svetovati glede ustrezne zaščite pred soncem, kot so npr. čim krajši čas sončenja, uporaba kreme za sončenje z ustreznim zaščitnim faktorjem in zaščita kože s primerno obleko(glejte poglavje 4. 5“ Medsebojno delovanje z drugimi zdravili in druge oblike interakcij”).

In the paper the main findings of the master's thesis Discourses- language, communication and other forms of interaction: stories of the handicapped are presented.
V prispevku so povzete temeljne ugotovitve raziskave iz magistrske naloge Diskurzi- jezik, komunikacijske dejavnosti in druge oblike interakcije: zgodbe oseb.

Paroxetine should not be used in combination with thioridazine, because, as with other drugs which inhibit the hepatic enzyme CYP450 2D6, paroxetine can elevate plasma levels of thioridazine(see section 4.5 Interactions with other medicinal products and other forms of interaction).
Paroksetin se ne sme uporabljati v kombinaciji s tioridazinom, saj lahko, podobno kot druga zdravila, ki zavirajo jetrni encim CYP450 2D6, tudi paroksetin poveča plazemske vrednosti tioridazina(glejte poglavje 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij).

Interaction with other medicinal products and other forms of interaction.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij.

The basis for referral was that there were divergences in the Summaries of Product Characteristics(SPC) of Risperdal Consta and associated names approved across EU Member States, with respect to the indication, the special warnings and precautions for use and the interaction with other medicinal products and other forms of interaction.
Osnova za napotitev so bile razlike med povzetki glavnih značilnosti zdravila Risperdal Consta in z njim povezanih imen v državah članicah EU pri indikacijah, posebnih opozorilih in previdnostnih ukrepih ter medsebojnem delovanju z drugimi zdravili in drugih vrstah interakcij.

(See sections 4.4 Special warnings and special precautions for use, 4.5 Interaction with other medicinal products and other forms of interaction and 5.2 Pharmacokinetic properties).
(Glejte poglavja 4. 4 Posebna opozorila in previdnostni ukrepi, 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij in 5. 2 Farmakokinetične lastnosti).

The basis for referral was that there were divergences in the Summaries of Product Characteristics(SPC) of Risperdal and associated names approved across EU Member States, with respect to the indications, the posology and method of administration, the contra-indications, the special warnings and precautions for use and the interaction with other medicinal products and other forms of interaction.
Osnova za napotitev so bile razlike med povzetki glavnih značilnosti zdravila Risperdal in z njim povezanih imen v državah članicah EU pri indikacijah, odmerjanju in načinu uporabe, kontraindikacijah, posebnih opozorilih in previdnostnih ukrepih ter medsebojnem delovanju z drugimi zdravili in drugih vrstah interakcij.

Further discrepancies also exist between Member States regarding sections 4.2 Method of administration, 4.5 Interactions with other Medicinal Products and other forms of Interaction, 4.6 Pregnancy and lactation and 6.2 Incompatibilities.
Nadaljnje neskladnosti med posameznimi državami članicami obstajajo tudi pri poglavjih 4. 2 Način uporabe, 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij, 4. 6 Nosečnost in dojenje ter 6. 2 Inkompatibilnosti.

Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients and is more likely to occur in patients who have been volume- depleted e. g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting, or who have severe renin-dependent hypertension(see sections 4.5“ Interaction with other medicaments and other forms of interaction” and 4.8“ Undesirable effects”).
Simptomatična hipotenzija je redka pri bolnikih s hipertenzijo brez zapletov, verjetnejša pa pri tistih s hipovolemijo, na primer zaradi zdravljenja z diuretiki, omejitve soli v prehrani, dialize, driske ali bruhanja, ali pri vseh s hudo reninsko odvisno hipertenzijo(glejte poglavji 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij in 4. 8 Neželeni učinki).

In addition, findings on clinical pharmacology were introduced in the sections on special warnings and precautions for use(4.4), interaction with other medicinal products and other forms of interaction(4.5) and the section on pharmacokinetic properties(5.2).
Poleg tega so bile v poglavja o posebnih opozorilih in previdnostnih ukrepih za uporabo(4. 4), medsebojnem delovanju z drugimi zdravili in drugih oblikah interakcij(4. 5) ter v poglavje o farmakokinetičnih lastnostih(5. 2) vključene ugotovitve o klinični farmakologiji.

The Referral procedure under Article 30 of Directive 2001/ 83/ EC, as amended for Risperdal Consta was initiated in order to resolve divergences amongst the nationally authorised Product Information texts across the EU and EEA Member States, in particular with respect to indications, special warnings and precautions for use and interaction with other medicinal products and other forms of interaction.
Napotitveni postopek za zdravilo Risperdal Consta je bil v skladu s členom 30 Direktive 2001/ 83/ ES, kakor je bila spremenjena, sprožen za razrešitev neskladij med informacijami o zdravilu med odobrenimi besedili v uporabi v posameznih državah članicah v EU in EGS, zlasti v zvezi s poglavji o indikacijah, posebnih opozorilih in previdnostnih ukrepih ter medsebojnem delovanju z drugimi zdravili in drugimi oblikami interakcij.